237056-94-9

Upstream product

• 17407-55-5 (S)-2-Hydroxy-3-methylbutanoic acid 
• 182621-40-5 (2S,3R)-[(S)-1-(benzyloxy)-3-methyl-1-oxobutan-2-yl]-3-(tert-butyldimethylsilyloxy)-2-methyldecanoate 
• 182621-38-1 (2S,3R)-3-(tert-butyldimethylsilyloxy)-2-methyl-decanoic acid 
• 158744-38-8 Ethyl 4(S)-(benzyloxyformamido)-3(S)-hydroxy-5-phenylpentanoate 
• 65138-05-8 (S)-2-hydroxy-3-methylbutyric acid benzyl ester 
• 1161-13-3 N-Cbz-L-Phe 
• 182621-41-6 (2S,3R)-[(S)-1-(benzyloxy)-3-methyl-1-oxobutan-2-yl]-3-hydroxy-2-methyldecanoate 

Downstream Products

• 159542-04-8 (2S,5S,6S,10R,11S)-5-Benzyl-10-heptyl-6-hydroxy-2-isopropyl-4,11-dimethyl-1,9-dioxa-4-aza-cyclododecane-3,8,12-trione 

Relevant academic research and scientific papers

Synthesis and evaluation of hapalosin and analogs as MDR-reversing agents

The marine natural product hapalosin and 22 analogs, which incorporated systematic substituent deletions or variations, were prepared. These compounds were evaluated in a cell-based assay for both MDR-reversing activity and general cytotoxicity. Some substituent modifications resulted in lower cytotoxicities, but most structural changes were either detrimental to or did not seriously alter the MDR-reversing activity.